Document text
National Center for Immunization & Respiratory Diseases
Influenza Work Group —Introduction
Dr. Jamie Loehr (Work Group Chair)
Advisory Committee on Immunization Practices
October 23, 2024
Influenza Work Group
ACIP Members
•Jamie Loehr (Chair)
•Robert Schechter
•Albert Shaw
•Keipp Talbot
Ex Officio
•Timothy Brennan (FDA)
•Uzo Chukwuma (IHS)
•Michael Ison (NIH)
•Cynthia Nolletti (FDA)
•Jo Resnick (FDA)
•Chris Roberts (NIH)Liaison Representatives and Consultants
•Robert Atmar
•Kevin Ault
•Ed Belongia
•Hank Bernstein
•Kris Bryant
•Doug Campos -Outcalt
•Sarah Coles
•Frances Ferguson
•Sandra Fryhofer
•Robert Hopkins
•Wendy Keitel
•Camille Kotton
•Marie -Michèle Léger
•Susan Lett
•Krissy Moehling•Zackary Moore
•Rebecca Morgan
•Flor Munoz
•Caitlin Newhouse
•Jesse Papenburg
•William Schaffner
•Ken Schmader
•Tamara Sheffield
•Angela Sinilaite
•Peter Szilagyi
•Matthew Zahn
CDC Lead
•Lisa Grohskopf
2
CDC Participants
•Lenee Blanton
•Karen Broder
•Alicia Budd
•Jessie Chung
•Jennifer DeCuir
•Sascha Ellington
•Tarayn Fairlie
•Jill Ferdinands
•Brendan Flannery
•Andrew Kroger
•Samantha Olson
•David Shay
•Tom Shimabukuro
•Naomi Tepper
3
Brief Note
Update concerning FluMist (Live Attenuated Influenza Vaccine, Trivalent; LAIV3)
•On September 20, 2024, FDA approved FluMist for self or caregiver administration.
•For the current 2024 -25 influenza season, FluMist is available for administration by
a healthcare provider only.
•It is anticipated that FluMist will be available for self or caregiver administration for
the 2025 -26 influenza season.
4https://www.fda.gov/vaccines -blood -
biologics/vaccines /flumist
2023 -24 Season Influenza Vaccine Effectiveness (VE)
Updates:
•2023–24 End of Season Influenza Vaccine Effectiveness – United States
⁻Dr. Sascha Ellington, Influenza Division, CDC/NCIRD
•This topic is presented for information and discussion. Issue:
•Influenza vaccine effectiveness (VE) varies and is assessed annually through several
CDC platforms focusing on laboratory -confirmed influenza outpatient visits and
hospitalizations in adult and pediatric populations.
•Preliminary 2023 -24 season VE estimates were presented at the February 2024
ACIP meeting.
5
Avian Influenza A(H5N1) Update
Updates:
•Highly Pathogenic Avian Influenza A(H5N1 ) Update
⁻Dr. Tom Shimabukuro; Deputy Director, Influenza Division, CDC/NCIRD
•This topic is presented for information and discussion. Issue:
•Influenza A(H5N1) has been detected in U.S. dairy herds in 14 U.S. states
•27 human cases have been reported during 2024 .
6https://www.cdc.gov/bird -flu/situation -summary/index.html
Vaccines for Children (VFC) Vote
Vote:
•A VFC resolution is proposed to add options for vaccination of 18 -year -olds who are
solid organ transplant recipients.
⁻Dr. Jeanne Santoli, CDC/NCIRDIssue:
•High -dose inactivated (HD -IIV3) and adjuvanted inactivated (aIIV3) influenza
vaccines are approved in the United States for ages ≥65 years.
•An evidence review of HD -IIV3 and aIIV3 for solid organ transplant (SOT) recipients
ages ≥6 months was presented at the June 2024 ACIP meeting.
•ACIP voted to recommend that HD -IIV3 and aIIV3 are acceptable options for SOT
recipients aged 18 through 64 years who are receiving immunosuppressive
medication regimens, without a preference over other age -appropriate inactivated
or recombinant vaccines.
7
For more information, contact CDC
1-800-CDC-INFO (232 -4636)
TTY: 1 -888-232-6348 www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the
official position of the Centers for Disease Control and Prevention.